Navigation Links
UCSF Fresno leading-edge study lends hope to emphysema patients
Date:10/21/2008

Patients in the Valley with emphysema might soon be breathing a little easier thanks to a new airway bypass study called the Exhale Airways Stents for Emphysema (EASE) trial. The trial principal is Dr. Karl Van Gundy aided by investigators Drs. Michael Peterson, Jose Joseph, Timothy Evans and Kathryn Bilello all pulmonologists at UCSF Fresno Medical Education Program. The study is a multi-center, international trial that is designed to evaluate the safety and effectiveness of this new and innovative procedure. There are only two other sites administering the trial in California besides UCSF Fresno UC Davis Medical Center and Cedars-Sinai Medical Center in Los Angeles.

A form of chronic obstructive pulmonary disease (COPD), emphysema is a progressive lung disease that keeps air trapped inside the lungs (not allowing it to escape) resulting in shortness of breath. Since the disease develops gradually over many years, symptoms of emphysema might not occur until irreversible damage has already happened.

"COPD is the fourth leading cause of death in the United States and a significant cause of disability in the world," said Dr. Peterson, who also is chief of medicine at UCSF Fresno Medical Education Program. "Very few new treatments have become available for this disease."

The EASE trial procedure creates new pathways in the walls of the natural airways that connect the damaged inner lung tissue and the larger natural air passages. Dr. Peterson said these new passageways may provide a pathway for the trapped air in the inner lung to escape by "bypassing" the collapsing small airways. These new pathways are created using a special needle through a bronchoscope.

After each new passage is made, a small drug-eluting stent (a wire mesh similar to what is used to keep coronary arteries open in heart disease) is implanted and provides support to keep the passageway open. Dr. Peterson said opening the airway allows
'/>"/>

Contact: Meghan Oreste
moreste@comcast.net
617-823-1441
Broncus Technologies
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
2. A study by the MUHC and McGill University opens a new door to understanding cancer
3. Study begins to reveal clues to the cause and progression of sepsis
4. Clones on task serve greater good, evolutionary study shows
5. New study warns limited carbon market puts 20 percent of tropical forest at risk
6. New study examines how rearing environment can alter navigation
7. Study links cat disease to flame retardants in furniture and to pet food
8. New continent and species discovered in Atlantic study
9. Study shows link between alcohol consumption and hiv disease progression
10. Feeling hot, hot, hot: New study suggests ways to control fever-induced seizures
11. Study finds environmental tests help predict hospital-acquired Legionnaires disease risk
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UCSF Fresno leading-edge study lends hope to emphysema patients
(Date:3/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) ... Global Strategic Business Report" report to their offering. ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... of World. Annual estimates and forecasts are provided ...
(Date:3/19/2015)... March 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... clip that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host ... way to pay, and ,a really big breakthrough in mobile ...
(Date:3/17/2015)... Emotient, the leader in facial expression ... availability of Emotient Analytics , the world,s ... facial expressions. The system analyzes videos of people ... services. It delivers audience response metrics - such ... derived from facial evidence of emotional states. Consumer ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... lawn grass come equipped with their own natural broad-spectrum ... plants around them., Cornell researchers have identified the ... that these lawn grasses exude from their roots in ... of para-tyrosine (p-tyrosine), one of the 20 common amino ...
... 7, 2007) FIJI Water, one of the fastest ... announced a Sustainable Growth Initiative today that will make ... achieve this, FIJI Water will account for the carbon ... then, through a combination of meaningful reductions and carbon-reducing ...
... Mass., Nov. 7, 2007 -- Researchers at Harvard University ... by nature, to reduce the accumulation of atmospheric carbon ... By electrochemically removing hydrochloric acid from the ocean ... (volcanic) rocks, the researchers say they can accelerate natural ...
Cached Biology News:Researchers discover natural herbicide released by grass 2FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change 2FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change 3FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change 4FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change 5Engineered weathering process could mitigate global warming 2Engineered weathering process could mitigate global warming 3
(Date:4/16/2015)... April 16, 2015 Cytokinetics, Incorporated (Nasdaq: ... first quarter results on Thursday, April 30, 2015 at ... management will host a conference call at 4:30 PM ... the company’s outlook for the future. , The conference ... from the homepage and in the Investor Relations section ...
(Date:4/16/2015)... According to the 2014 Liberty Mutual ... was ranked first among the leading causes of ... pushing, pulling, holding, carrying, or throwing and cost ... Round Company takes statistics like this very seriously. ... develop and design equipment that prevents these injuries ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
(Date:4/16/2015)... Calif. , April 16, 2015  Scientists from ... "New Drugs on the Horizon," at the American Association ... Philadelphia, PA on Sunday, April 19, 2015 ... Ph.D., Cleave,s Director of Biology, will present new in ... a first-in-class, oral inhibitor of p97, a critical enzyme ...
Breaking Biology Technology:Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3
... 17 Genzyme Corp.,(Nasdaq: GENZ ) announced ... has approved a supplemental indication for Thyrogen(R) (thyrotropin,alfa ... radioiodine to ablate,or destroy, the remaining thyroid tissue ... Remnant ablation is a procedure that patients,commonly undergo ...
... Patients Had Confirmed Partial Responses (25%); ... Breast Cancer Symposium, HAYWARD, Calif., Dec. 17 ... announced that its Hsp90 inhibitor,tanespimycin, demonstrated meaningful antitumor ... patients with HER2-positive metastatic breast cancer,when administered in ...
... Va., Dec. 17 Innocoll, Inc., a,privately ... has,closed an equity financing investment to raise ... stock in a private placement with three,institutional ... with NewSmith,Asset Management LLP and Morgan Stanley ...
Cached Biology Technology:Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation 2Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation 3Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation 4Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer 2Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer 3Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer 4Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer 5Innocoll Announces Closing of $30 Million Equity Financing Investment 2Innocoll Announces Closing of $30 Million Equity Financing Investment 3Innocoll Announces Closing of $30 Million Equity Financing Investment 4Innocoll Announces Closing of $30 Million Equity Financing Investment 5
...
Performance, mycoplasma, virus, and endotoxin tested. Collected from calves 14 days old or less...
...
Mus musculus junctophilin 2 (Jph2) Antigen: Recombinant Protein...
Biology Products: